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ABSTRACT 
 
This is a review on cigarette smoking and Parkinson’s disease (PD). The relationship between 
cigarette smoking and Parkinson’s disease is very controversial.  Cigarette smoking is an 
established risk factor for various diseases such as lung cancer, COPD and heart disease. 
However, beneficial effects have been debated over the years.  It was in the late 1950’s that 
studies reported a negative association between smoking and Parkinson’s disease.  More 
recently, several epidemiological studies have found a significant negative association between 
cigarette smoking and PD.  That is, patients who smoke are 50% less likely to have PD when 
compared to their non-smoker counterparts. This suggests that cigarette smoking may have a 
“neuroprotective” effect on PD.   
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PARKINSON’S DISEASE: 
PREVALENCE, ETIOLOGY AND 
THERAPY 
 
Parkinson’s disease (PD), is the second most 
common neurodegenerative disease in the U.S. 
(Bennett et al., 1996), it affects 1 million 
Americans with an incidence of 
50,000cases/year (Kurkland, 1958).  PD 
occurs in ~1% of the population over the age 
of 55. PD was first described as a “shaking 
palsy” of unknown origin by James Parkinson 
in 1917.  PD is a movement disorder that is 
characterized by selective damage to 
dopaminergic nigrostriatal neurons that lead to 
motor deficits including rigidity, tremor, 
bradykinesia and possibly dementia (Bezard, 
2001; Olanow and Tatton, 1999). 
 
The primary pathology of PD is believed to 
involve the loss of dopaminergic neurons in 
the substantia nigra, with a resultant decline of 
dopamine in the striatum (Quik and Kulak, 
2002). Studies have shown that PD patients 
often exhibit low levels of brain dopamine, 
which stems from the degeneration of the 
nigrostriatal dopaminergic pathway, which is 
made of dopaminergic neurons whose cell 
bodies are located in the substantia nigra pars 
compacta and whose projecting axons and 
nerve terminals are found in the striatum (Daur 
and Pzredborski., 2003).  The most 
characteristic histological findings are loss of 
substantia nigra neurons, with Lewy bodies in 
the surviving neurons (Gibb and Lees, 1988). 
 
The etiology of PD is unknown; however it is 
believed to be due to one or more of the 
following: age, genetics and/or environmental 
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factors such as pesticides. 1-methyl-4-phenyl-
1, 2, 3, 6-tetrahydropyridine (MPTP) is a 
chemical that is related to the opioid analgesic 
drugs.  MPTP is oxidized by monoamine 
oxidase B (MAO-B) to form 1-methyl-4-
phenyl-pyridinium ion (MPP+), which is taken 
up by dopaminergic neurons and leads to cell 
death.   It has been reported (Langston et al., 
1984) that injections of MPTP in squirrel 
monkeys resulted in parkinsonism. The 
symptoms and brain structures of MPTP-
induced Parkinson's are fairly 
indistinguishable to the point that MPTP may 
be used to simulate the disease in order that 
scientists may study Parkinson's physiology 
and possible treatments within the laboratory. 
 
The most common used treatment of PD is 
dopamine replacement therapy.  Drugs used to 
treat PD include catechol-O-methyltransferase 
(COMT) inhibitors, dopamine receptor 
agonists, MAO-B inhibitors and most 
commonly the dopamine agonist, Levodopa. 
 
IMPACT OF CIGARETTE SMOKING ON 
GENERAL HEALTH 
 
Cigarette smoke is composed of more than 
4700 chemical compounds including nicotine, 
the addictive substance of cigarettes, carbon 
monoxide, lead, cadmium and polycyclic 
aromatic hydrocarbons. According to the 
Centers for Disease Control and Prevention 
(CDC), in 2001 a reported 46.2 million 
Americans were smokers. This accounted for 
nearly 23% of all adults, meaning 1 in 4 adults 
smoke. Smoking kills more Americans than 
alcohol, car accidents, suicide, AIDS, 
homicide, and illegal drugs combined.  Each 
year an average of 440,000 deaths are related 
to smoking.  Tobacco use costs the United 
States ~$100 billion each year in direct 
medical expense and lost productivity 
(Morbidity and Mortality Weekly Report).  
Smoking during pregnancy accounts for low-
birth weight, pre-mature birth and infant death 
(U.S. Dept. of Health and Human Services, 
2001).  It also increases neonatal health care 
costs (Adams et al., 2002). Cigarette smoking 
has been linked to common causes of death in 
the elderly and contributes to death and 
disability associated with chronic illnesses 
common in this age group (Bratzler et al., 
2002). 
 
Cigarette smoke contains carcinogens that 
alter biochemical defense systems that lead to 
deleterious effects on the respiratory tract, 
heart, pancreas, reproductive tract and other 
organs (Ostergaard, 1977). Smoking has been 
attributed to causing cancer, chronic 
obstructive lung disease (COPD) and 
cardiovascular disease.  Smoking is believed 
to be the most preventable cause of death in 
the United States to date. However, the 
beneficial effects of cigarette smoke are rarely 
discussed. Smoking has been observed to 
reduce the incidence of various diseases 
including endometrial cancer, ulcerative 
colitis, hypertension during pregnancy, 
Alzheimer’s disease and PD (English et al., 
1995; Graves et al., 1991; Van Duijin and 
Hofman, 1991). 
 
IMPACT OF CIGARETTE SMOKING ON 
PARKINSON’S DISEASE 
 
Cigarette smoking is the most preventable 
cause of death in the United States today.  
Cigarette smoking has been studied in relation 
to various neurological disorders, such as 
Alzheimer’s disease and Parkinson’s disease.  
However, the relationship between cigarette 
smoking and PD remains to be controversial.  
Several epidemiological studies have found a 
negative association between cigarette 
smoking and PD.  It is reported that patients 
who smoke are 50% less likely to have PD 
when compared to their non-smoking 
counterparts.  This suggests that cigarette 
smoking might exert a neuroprotective effect.  
The hypothesis is that cigarette smoking 
 95
protects against neurodegeneration thereby 
preventing PD.  This is a review of cigarette 
smoking and PD. 
 
The first report of the negative association 
between cigarette smoke and PD is that of 
Dorn, 1959 who reported decreased PD 
occurrence among smokers after conducting 
mortality studies.  In the 1970’s more studies, 
both case-control and longitudinal, were 
published and confirmed a negative 
association of smoking with PD.   In 1992, a 
comprehensive study was conducted to test the 
hypothesis that cigarette smoke protects 
against the development of PD. A group of 
14,436 twins from the National Academy of 
Sciences-National Research Council World 
War II Veteran Twins Registry were 
interviewed as part of the study.  This study 
investigated the association of cigarette 
smoking behaviors and PD.  The study showed 
that the risk of PD is inversely correlated to 
the dose or pack-years smoked.  These results 
suggested that there is a biologic protective 
effect of cigarette smoking on PD and that this 
is not just an epidemiological theory.   
 
Several epidemiological studies have been 
published on the negative association between 
smoking and PD. Numerous studies have 
concluded that there was no significant 
difference between patients with PD and 
controls exposed to smoke (Rajput, 1984; 
Wang et al., 1993; McCann et al., 1998).  
Rajput identified 118 cases of idiopathic PD 
and 236 controls and determined that there 
was no significant risk for ever-smoked and 
PD from non-smokers. Although these studies 
failed to detect a significant association 
between smoking and PD, others confirmed a 
negative association.  Mayeux et al. (1994) 
examined smoking in relation to PD in 
Manhattan, NY and concluded that PD reduces 
smoking.  Godwin-Austen et al. (1982) also 
demonstrated a negative association between 
smoking habits and PD.  Furthermore, a 
population-based case-control study conducted 
by the Henry Ford Health System database 
demonstrated a strong negative association 
between smoking and PD (Gorell et al., 1999). 
Several other epidemiological studies have 
also found a beneficial effect of smoking in 
PD (Fratiglioni and Wang, 2000; Hernan et al., 
2001; Checkoway et al., 2002).  
 
Morens and his group (1995) reviewed several 
epidemiological reports associating cigarette 
smoking and PD. They found various biases in 
the 46 articles they reviewed including 
selective mortality, cause-and-effect, and 
smoking-associated symptoms.  Moreover, the 
authors underlined that the negative 
association was due to a direct chemical 
protective effect of smoking; and found that 
smoking protects against toxic neuronal 
damage, and that smoking is associated with 
the inhibition of free radical damage to cells 
within the substantia nigra. This critical review 
provided strong evidence for the hypothesis on 
the negative association with PD and revealed 
the need for direct animal studies.   
 
Since it has been suggested that there is a 
negative association of cigarette smoking with 
PD, in vitro studies have tested the effect of 
cigarette smoke exposure on MPTP-induced 
neuronal changes. Parain et al. (2003) 
examined the neuroprotective effect of 
cigarette smoke and nicotine on a MPTP-
induced mouse model of PD.  Chronic nicotine 
treatment resulted in a significant reduction in 
the loss of dopaminergic neurons in the 
substantia nigra.  These authors found that 
nicotine and low exposure to cigarette smoke 
may have a neuroprotective effect on the 
dopaminergic nigrostriatal system. 
Furthermore, Quik et al. (2006) investigated 
the effect of long-term nicotine treatment 
against nigrostriatal damage in non-human 
primates.  Results showed that levels of striatal 
tyrosine hydroxylase, dopamine transporter, 
vesicular monoamine transporter, dopamine 
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and nicotinic receptors were greater in 
nicotine-treated MPTP-lesioned primates 
when compared to lesioned primates not 
receiving nicotine. This suggests that nicotine 
may contribute to the lower incidence of PD 
among smokers.  
 
Cigarette smoke has also been shown to inhibit 
monoamine oxidase (MAO) activity, and 
MAO is known to breakdown dopamine 
(Fowler et al., 2000).  Several studies also 
suggest that nicotine stimulates dopamine 
release (Janson et al., 1992; Westfall et al., 
1967; Clarke et al., 1985); thereby conceivably 
suppressing early signs of PD.  Numerous 
studies have also shown that cigarette smoke 
contains more than 1014 free radicals per puff 
(Church and Pryor, 1985; Bluhn et al., 1971; 
Forbes et al., 1967; Pryor, 1992; Pryor and 
Ston., 1993; Pryor et al., 1990). However, 
although cigarette smoke contains several free 
radicals, it also contains carbon monoxide 
(CO), and CO seems to be protective against 
hydrogen peroxide (H2 O2) -induced membrane 
damage (McKenney et al., 1990; Metz et al., 
1974; Sagone et al., 1975).  CO also inhibits 
neural MAO-B-associated metabolism of 
dopamine to produce H2 O2 and possibly 
creates a protective nigral “reducing 
environment” (Baron, 1986), therefore 
suppression of free radical generation in early 
life could possibly lead to reduced risk of PD 
by preserving  
dopamine producing cells. 
 
CONCLUSIONS 
 
A review of a portion of the existing literature 
revealed that there is a definite link between 
cigarette smoking and PD.  Secondly, there is 
a negative association between smoking and 
PD.  Furthermore, direct animal studies predict 
a possible protective effect of smoking on the 
development of PD and parkinsonian 
symptoms, but the mechanism by which this 
occurs is un-clear. Therefore the mechanism 
by which smoking may impart a 
neuroprotective effect remains to be elucidated 
in an animal model.  Determining the 
underlining mechanism by which smoke 
imparts its effects may aid in defining the 
etiology and pathogenesis of PD.  
Furthermore, it may be utilized in the 
development of targeted drug therapies for PD.  
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